Tag - Bert Hazlett

Analysts for Stifel and BTIG launched coverage of Rani Therapeutics (NASDAQ:RANI) with “buy” ratings and price targets of $24, respectively. The stock closed at $17.76 on Aug. 24. “Rani appears to have cracked the...